• Explore /
  • Poster
  • / Randomized phase II study of 3 versus 6 courses of neoadjuvant carboplatin-paclitaxel chemotherapy in stage IIIC or IV epithelial ovarian cancer.

Randomized phase II study of 3 versus 6 courses of neoadjuvant carboplatin-paclitaxel chemotherapy in stage IIIC or IV epithelial ovarian cancer.

Abstract Poster

Authors

null

Claudio Zamagni

Addarii Medical Oncology Unit, S.Orsola-Malpighi Hospital, Bologna, Italy

Claudio Zamagni , Myriam Perrone , Vincenzo Dario Mandato , Alessandra Bologna , Daniela Rubino , Giorgia Zucchini , Nuria Maria Asensio Sierra , Elena Barbieri , Marta Cubelli , Pierandrea De Iaco , Martino Abrate

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Ovarian Cancer

Clinical Trial Registration Number

2013-002520-17

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr TPS5624)

DOI

10.1200/jco.2014.32.15_suppl.tps5624

Abstract #

TPS5624

Poster Bd #

399B

Abstract Disclosures

Similar Posters

First Author: Gwenael Ferron

First Author: Sara P. Myers

First Author: Severine Guiu Lahaye

First Author: George Somlo